AMGN

FDA Approval of Uplizna: The FDA has approved Amgen Inc.'s Uplizna as the first treatment for adult patients with Immunoglobulin G4-related disease (IgG4-RD), supported by data from the MITIGATE trial showing significant reductions in disease flares.

Stock Performance and Predictions: Amgen's stock is currently down 1.05% at $306.59, with analysts using technical analysis to predict future price movements based on trends and moving averages.

FDA Approval of UPLIZNA: Amgen's UPLIZNA has been approved by the FDA as the first treatment for adults with Immunoglobulin G4-related disease (IgG4-RD), demonstrating an 87% reduction in flare risk compared to placebo and offering corticosteroid-free remission options.

MITIGATE Trial Findings: The MITIGATE trial showcased UPLIZNA's efficacy in reducing disease activity, achieving significant improvements in flare rates and complete remission among patients, while also highlighting its potential for treating other autoimmune diseases.

FDA Approval: Amgen's Uplizna has received expanded FDA approval for treating immunoglobulin G4-related disease (IgG4-RD) in adults, a chronic immune disorder that can lead to organ dysfunction.

Clinical Trial Results: The approval is supported by late-stage clinical trial results showing an 87% reduction in the risk of disease flare compared to a placebo.

FDA Approval of UPLIZNA: Amgen's UPLIZNA has been approved by the FDA as the first treatment for adults with Immunoglobulin G4-related disease (IgG4-RD), demonstrating an 87% reduction in flare risk compared to placebo and offering corticosteroid-free remission options.

MITIGATE Trial Findings: The MITIGATE trial showcased UPLIZNA's efficacy in reducing disease activity, achieving significant improvements in flare rates and complete remission among patients, while also highlighting its potential for treating other autoimmune diseases.

Impact of Tariffs on Biopharma Industry: President Trump's newly announced tariffs could significantly affect the biopharma sector, with potential costs reaching $20 billion due to a 10% tariff on $200 billion worth of pharmaceutical imports. Companies like Vertex and Alnylam are well-positioned, while concerns arise for firms like Regeneron due to their manufacturing presence in Ireland.

Market Volatility and Resilience: Goldman Sachs anticipates continued volatility in the biotechnology sector amid economic uncertainty and unclear healthcare policies, although biopharma companies are generally resilient due to high profit margins and global operations. The analysis highlights limited exposure to tariffs from Canada and Mexico, but warns that tariffs on drugs made outside the U.S. could raise manufacturing costs.

Market Reaction to Job Report: Despite the U.S. economy adding 228,000 jobs in March, significantly surpassing expectations, Wall Street experienced a sharp decline due to escalating fears of a trade war following China's retaliatory tariffs on U.S. goods.

Stock Performance Overview: Major stock indices fell sharply, with the Dow entering correction territory and the Nasdaq hitting bear market status, while bonds saw increased demand as Treasury yields dropped.

Sabra Health Care REIT Performance: Sabra Health Care REIT, Inc. (SBRA) has an almost 7% dividend yield, with a recent price target increase from $17 to $18 following better-than-expected earnings and sales results.

Kinsale Capital and Amgen Updates: Kinsale Capital Group, Inc. (KNSL) is set to report Q1 financial results on April 24, while Amgen Inc. (AMGN) received FDA approval for a new treatment, contributing to positive stock performance for both companies.

Impact of New Tariffs: President Trump's new tariffs, including a 10% baseline on all imports, have led to significant declines in major U.S. tech and retail stocks, raising fears of increased costs and potential recession risks as companies like Apple and Walmart face higher expenses.

Market Reactions and Predictions: The tariffs are expected to disrupt global supply chains, with analysts predicting a reduction in U.S. economic growth by up to 1.5 percentage points, while sectors such as pharmaceuticals and energy stocks showed mixed reactions amid concerns over a global economic slowdown.

Market Performance: The Dow Jones Industrial Average is experiencing a decline, trading 149 points (0.4%) lower on Tuesday afternoon.

Key Contributors: Shares of Johnson & Johnson and Merck are identified as the primary contributors to this intraday drop in the index.

Tariff Implications for Pharmaceuticals: President Trump's proposal to impose tariffs of up to 25% on imported pharmaceuticals could significantly impact the industry, which has been protected by previous trade agreements. Analysts warn that companies like Merck, AbbVie, and Amgen may face the highest risks due to their manufacturing locations and tax strategies.

Industry Response and Challenges: The pharmaceutical industry is advocating for a gradual implementation of any tariffs, citing the lengthy and costly process of establishing new manufacturing plants in the U.S. While some companies are already increasing domestic production, analysts suggest that passing additional costs onto consumers may be necessary, particularly for low-margin generic drugs.

Impact of Tariffs on Stock Market: The Trump administration's newly announced tariffs led to a significant decline in the stock market, with the S&P 500 dropping 4.8%, although the pharmaceutical and biotech sectors experienced relatively milder impacts due to temporary exemptions from these tariffs.

Pharmaceutical Industry Developments: Despite potential future tariffs targeting pharmaceutical exports, companies like Amgen continue to make progress, such as receiving FDA approval for their drug Uplizna, which treats a rare immune disorder, highlighting ongoing innovation in the sector amidst economic challenges.

AMGEN INC Rating: AMGEN INC (AMGN) received an 87% rating from Validea's Multi-Factor Investor model, indicating strong interest based on its fundamentals and valuation in the Biotechnology & Drugs industry.

Pim van Vliet's Strategy: The strategy, developed by Pim van Vliet, focuses on low volatility stocks with high momentum and net payout yields, emphasizing that such stocks can outperform higher volatility ones with less risk.

Market Overview: The S&P 500, Dow Jones, and Nasdaq are all down as investors await President Trump's announcement on new tariffs, which could impact economic growth and corporate earnings. Despite positive labor market news, stock indexes remain under pressure due to tariff concerns.

Stock Movements: Major tech stocks like Tesla and Nvidia are experiencing declines, while pharmaceutical companies face losses following leadership changes in the Department of Health and Human Services. Conversely, DoorDash and Rocket Companies saw gains after positive developments.

Amgen Performance: Amgen is the worst performing Dow component today, down 1.9%, but has a year-to-date gain of 15.5%.

Other Dow Components: NVIDIA is also down 1.3%, while Honeywell International is up 0.3% for the day.

DIA Stock Performance: DIA's stock has a 52-week low of $376.14 and a high of $451.55, with the latest trade at $419.44, indicating its current position relative to historical performance.

ETFs Trading Dynamics: Exchange traded funds (ETFs) function like stocks but involve trading "units" that can be created or destroyed based on investor demand, impacting the underlying assets held within the ETFs.

Amgen's Stock Performance: Amgen (AMGN) closed at $310.09, up 1.44%, outperforming the S&P 500 and other major indices which experienced significant losses. The company is expected to report a 5.56% increase in EPS for the upcoming earnings disclosure.

Valuation and Analyst Insights: Amgen is currently trading at a Forward P/E ratio of 14.82, below the industry average, indicating it may be undervalued. The Zacks Rank system rates Amgen as #3 (Hold), reflecting stable analyst estimates and suggesting cautious optimism about its future performance.

Healthcare Stocks and Dividends: Investors often shy away from healthcare stocks due to the lack of reliable dividend payers, but companies like Amgen and AbbVie stand out with attractive dividend policies and consistent increases in their payouts.

Company Performance Highlights: Amgen reported a 19% revenue increase to over $33.4 billion, while AbbVie saw nearly 4% growth in total net revenue to $56.3 billion, both maintaining strong pipelines and future growth projections despite rising costs affecting profitability.

Market Performance: Shares of Amgen and IBM are driving strong returns, contributing to a rise in the Dow Jones Industrial Average by 113 points (0.3%).

Index Impact: The positive performance of Amgen Inc. and International Business Machines Corp. is helping boost the overall index during intraday trading.

Biotech ETF Performance: The SPDR S&P Biotech ETF is down approximately 4.4% in afternoon trading, with significant declines in individual stocks such as Vaxcyte (down 50.5%) and Capricor Therapeutics (down 18.3%).

Market Commentary: The opinions expressed in the article are those of the author and do not necessarily represent the views of Nasdaq, Inc.

AMGEN INC Rating: AMGEN INC (AMGN) received an 87% rating from Validea's Multi-Factor Investor model, indicating strong interest based on its fundamentals and valuation in the Biotechnology & Drugs industry.

Pim van Vliet's Strategy: The strategy, developed by Pim van Vliet, focuses on low volatility stocks with high momentum and net payout yields, emphasizing that such stocks can outperform higher volatility ones with less risk.